The Role of Nuclear Receptors in Prostate Cancer

por Shiota, Masaki, Fujimoto, Naohiro, Kashiwagi, Eiji, Eto, Masatoshi
Publicado 2019

Clinical outcome of transperitoneal ureterocutaneostomy using the transverse mesocolon

por FURUBAYASHI, NOBUKI, NEGISHI, TAKAHITO, KASHIWAGI, EIJI, FUKUDA, ATSUSHI, NAKAMURA, MOTONOBU
Publicado 2013

An oral first‐in‐class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer

por Ushijima, Miho, Shiota, Masaki, Matsumoto, Takashi, Kashiwagi, Eiji, Inokuchi, Junichi, Eto, Masatoshi
Publicado 2022

Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer

por Hirata, Yu, Shiota, Masaki, Kobayashi, Takeshi, Kashiwagi, Eiji, Takeuchi, Ario, Inokuchi, Junichi, Tatsugami, Katsunori, Eto, Masatoshi
Publicado 2019

Percutaneous sclerotherapy with OK-432 for lymphocele after pelvic or para-aortic lymphadenectomy: preliminary results

por Kashiwagi, Eiji, Ono, Yusuke, Yano, Hiroki, Kosai, Shinya, Nagai, Keisuke, Tanaka, Kaishu, Higashihara, Hiroki, Tomiyama, Noriyuki
Publicado 2022

Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer

por Kashiwagi, Eiji, Ide, Hiroki, Inoue, Satoshi, Kawahara, Takashi, Zheng, Yichun, Reis, Leonardo O., Baras, Alexander S., Miyamoto, Hiroshi
Publicado 2016

The interaction between androgen receptor and semenogelin I: a synthetic LxxLL peptide antagonist inhibits the growth of prostate cancer cells

por Li, Peng, Chen, Jinbo, Kashiwagi, Eiji, Mizushima, Taichi, Han, Bin, Inoue, Satoshi, Ide, Hiroki, Izumi, Koji, Miyamoto, Hiroshi
Publicado 2018

Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer

por Kashiwagi, Eiji, Shiota, Masaki, Masaoka, Hiroyuki, Imada, Kenjiro, Monji, Keisuke, Takeuchi, Ario, Inokuchi, Junichi, Tatsugami, Katsunori, Eto, Masatoshi
Publicado 2020

Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide

por Kashiwagi, Eiji, Shiota, Masaki, Lee, Ken, Monji, Keisuke, Naganuma, Hidekazu, Matsumoto, Takashi, Takeuchi, Ario, Inokuchi, Junichi, Eto, Masatoshi
Publicado 2022

Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1

por Kawahara, Takashi, Kashiwagi, Eiji, Ide, Hiroki, Li, Yi, Zheng, Yichun, Miyamoto, Yurina, Netto, George J., Ishiguro, Hitoshi, Miyamoto, Hiroshi
Publicado 2015

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone

por Akitake, Naoko, Shiota, Masaki, Obata, Hirofumi, Takeuchi, Ario, Kashiwagi, Eiji, Imada, Kenjiro, Kiyoshima, Keijiro, Inokuchi, Junichi, Tatsugami, Katsunori, Eto, Masatoshi
Publicado 2018

Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy

por Shiota, Masaki, Fujimoto, Naohiro, Imada, Kenjiro, Kashiwagi, Eiji, Takeuchi, Ario, Inokuchi, Junichi, Tatsugami, Katsunori, Kajioka, Shunichi, Uchiumi, Takeshi, Eto, Masatoshi
Publicado 2018

FOXO1 inactivation induces cisplatin resistance in bladder cancer

por Ide, Hiroki, Goto, Takuro, Teramoto, Yuki, Mizushima, Taichi, Jiang, Guiyang, Nagata, Yujiro, Inoue, Satoshi, Baras, Alexander S., Kashiwagi, Eiji, Miyamoto, Hiroshi
Publicado 2020

Validation of user-friendly models predicting extracapsular extension in prostate cancer patients

por Blas, Leandro, Shiota, Masaki, Nagakawa, Shohei, Tsukahara, Shigehiro, Matsumoto, Takashi, Lee, Ken, Monji, Keisuke, Kashiwagi, Eiji, Inokuchi, Junichi, Eto, Masatoshi
Publicado 2023

ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression

por Kawahara, Takashi, Shareef, Hasanain Khaleel, Aljarah, Ali Kadhim, Ide, Hiroki, Li, Yi, Kashiwagi, Eiji, Netto, George J., Zheng, Yichun, Miyamoto, Hiroshi
Publicado 2015

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer

por Chikamatsu, Sotaro, Shiota, Masaki, Yamada, Shigetomo, Blas, Leandro, Matsumoto, Takashi, Kashiwagi, Eiji, Inokuchi, Junichi, Shiga, Ken-ichiro, Yokomizo, Akira, Eto, Masatoshi
Publicado 2022

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer

por Yamada, Shigetomo, Shiota, Masaki, Blas, Leandro, Matsumoto, Takashi, Kashiwagi, Eiji, Takeuchi, Ario, Inokuchi, Junichi, Shiga, Ken-ichiro, Yokomizo, Akira, Eto, Masatoshi
Publicado 2022

Equol inhibits prostate cancer growth through degradation of androgen receptor by S‐phase kinase‐associated protein 2

por Itsumi, Momoe, Shiota, Masaki, Takeuchi, Ario, Kashiwagi, Eiji, Inokuchi, Junichi, Tatsugami, Katsunori, Kajioka, Shunichi, Uchiumi, Takeshi, Naito, Seiji, Eto, Masatoshi, Yokomizo, Akira
Publicado 2016

Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression

por Kashiwagi, Eiji, Inoue, Satoshi, Mizushima, Taichi, Chen, Jinbo, Ide, Hiroki, Kawahara, Takashi, Reis, Leonardo O, Baras, Alexander S, Netto, George J, Miyamoto, Hiroshi
Publicado 2018

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants

por Shiota, Masaki, Dejima, Takashi, Yamamoto, Yoshiaki, Takeuchi, Ario, Imada, Kenjiro, Kashiwagi, Eiji, Inokuchi, Junichi, Tatsugami, Katsunori, Kajioka, Shunichi, Uchiumi, Takeshi, Eto, Masatoshi
Publicado 2018